OmniAb, Inc. (OABI)

OmniAb's stock price has been affected by several events in the past six months. The company reported Q4 and full-year 2025 financial results, with Q4 revenue missing analyst estimates and full-year revenue declining from 2024. OmniAb participated in the Leerink Partners Global Healthcare Conference. The company launched OmniUltra, expanding its reach into new markets. There was insider selling activity. Analyst ratings were mixed, with some reiterating "Buy" ratings, while the stock experienced a pullback, resulting in a one-year loss for stockholders.

Based on the available information, there is no explicit indication of demand seasonality for OmniAb, Inc.'s products and services. The company's revenue streams are tied to the ongoing research and development cycles of its pharmaceutical and biotechnology partners, which are generally not seasonal.

OmniAb, Inc. is a technology company specializing in licensing discovery research platforms to pharmaceutical, biotechnology companies, and academic institutions, focusing on therapeutic antibody discovery technologies. The company's core offering is the OmniAb platform, which uses genetically modified animals to generate human sequence antibodies optimized for therapeutic use. OmniAb's business model includes upfront payments, milestone payments, and royalties from partners' product sales.

OmniAb, Inc. is headquartered in Emeryville, California, and has an Ion Channel Technology Center in Durham, North Carolina. The company's business model focuses on licensing its technology worldwide, indicating a broad geographic presence through partnerships with global pharmaceutical and biotech companies.

OmniAb's brand reputation in the past year has been characterized by positive developments in its technology and partnerships, despite a decline in stock price. The company has a consensus "Hold" rating from analysts, with some reiterating "Buy" ratings. Strong partner engagement and program growth, new technology launches like OmniUltra, program advancement, and improved operational efficiency have positively affected its reputation.

OmniAb, Inc. has a diverse ownership structure including institutional shareholders, insiders, and retail investors. Major institutional owners include Whitefort Capital Management, BlackRock, and Vanguard Group. Significant individual and private equity owners include Avista Capital Managing Member V LLC, Avista Capital Holdings, Robert Goldstein, and Matthew Foehr.